Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SO-C101 as Monotherapy and in Combination With Pembrolizumab in Advanced/Metastatic Solid Tumors
NCT04234113Phase 1Terminated
- Sponsor
- SOTIO Biotech
- Start
- Jun 2019
- Primary completion
- Aug 2024
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Fc-Fusion Proteins
- Countries
- 4
01
Overview
Phase 1, open-label trial of nanrilkefusp alfa in solid tumor (17 arms), sponsored by SOTIO Biotech. Primary endpoints: Number of Participants With Dose-limiting Toxicities, Number of Participants With Adverse Events and 4 more. Started Jun 2019; status: terminated.
02
Drugs
nanrilkefusp alfa
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04234113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04234113.